Gene therapy may activate stem cells in heart failure patients

February 22, 2013
Gene therapy may activate stem cells in heart failure patients
Delivery of an SDF-1 encoding plasmid acts a homing signal for stem cells and improves clinical status in patients with symptomatic heart failure due to ischemic cardiomyopathy, according to a study published online Feb. 21 in Circulation Research.

(HealthDay)—Delivery of an SDF-1 encoding plasmid (JVS-100) acts a homing signal for stem cells and improves clinical status in patients with symptomatic heart failure due to ischemic cardiomyopathy (IsCM), according to a study published online Feb. 21 in Circulation Research.

Marc Penn, M.D., from Summa Health System in Akron, Ohio, and colleagues conducted a phase I, open-label, dose-escalation study (5, 15, or 30 mg of JVS-100 via endomyocardial injection) with 12 months follow-up in subjects with IsCM. The 17 subjects had New York Heart Association (NYHA) Class III , with an ≤40 percent on stable medical therapy.

The researchers found that at one month and four months the primary safety end point of no major adverse cardiac events was met. All cohorts demonstrated improvements in six-minute walk distance (6MWd), quality of life (QOL), and NYHA class at four months. Improvements over baseline in 6MWd were seen in the 15-mg and 30-mg dose groups (15 mg: Median [Range]: 41 [3 to 61] m; 30 mg: 31 [22 to 74] m), as were improvements in QOL (15 mg: −16 [+1 to −32] points; 30 mg: −24 [+17 to −38] points). Improvements in symptoms were maintained at 12 months.

"These data highlight the importance of defining the of stem cell-based tissue repair and suggest that over-expression of SDF-1 via gene therapy is a strategy for improving heart failure symptoms in patients with IsCM," the authors write.

One author is named as an inventor on for the use of SDF-1 to treat cardiovascular disease that have been licensed by Juventas Therapeutics, which funded the study.

Explore further: Stem cell 'homing' signal may help treat heart failure patients

More information: Abstract
Full Text
Editorial

Related Stories

Stem cell 'homing' signal may help treat heart failure patients

February 21, 2013
In the first human study of its kind, researchers activated heart failure patients' stem cells with gene therapy to improve their symptoms, heart function and quality of life, according to a study in the American Heart Association ...

SCAI: Ixmyelocel-T studied for dilated cardiomyopathy

May 15, 2012
(HealthDay) -- For patients with dilated cardiomyopathy, treatment with an autologous bone marrow-derived, expanded multi-cell product, ixmyelocel-T, is well tolerated and associated with improved symptoms at one year, according ...

FDA: Zofran 32-mg dose pulled from market

December 6, 2012
(HealthDay)—The 32-mg, single intravenous dose of Zofran (ondansetron), an anti-nausea drug, is being removed from the market due to its potential to cause serious, even fatal, cardiac damage, according to a Drug Safety ...

FDA announces new limits on high-dose simvastatin (Zocor)

June 9, 2011
The United States Food and Drug Administration (FDA) today announced new limitations to the use of high-dose simvastatin, due to the increased risk of muscle pain and weakness (myopathy) and in rare cases, kidney damage and ...

Donepezil found helpful in dementia with lewy bodies

July 31, 2012
(HealthDay) -- For patients with dementia with Lewy bodies (DLB), treatment with 5 or 10 mg/day donepezil is associated with significant cognitive, behavioral, and global function improvements, according to research published ...

New therapy for heart failure may enhance body's stem cell response at cardiovascular injury site

February 21, 2013
Cardiovascular disease specialists at Florida Hospital Pepin Heart Institute and Dr. Kiran C. Patel Research Institute affiliated with the University of South Florida announced they have enrolled their first patients into ...

Recommended for you

Five vascular diseases linked to one common genetic variant

July 27, 2017
Genome-wide association studies have implicated a common genetic variant in chromosome 6p24 in coronary artery disease, as well as four other vascular diseases: migraine headache, cervical artery dissection, fibromuscular ...

Could aggressive blood pressure treatments lead to kidney damage?

July 18, 2017
Aggressive combination treatments for high blood pressure that are intended to protect the kidneys may actually be damaging the organs, new research from the University of Virginia School of Medicine suggests.

Quantifying effectiveness of treatment for irregular heartbeat

July 17, 2017
In a small proof-of-concept study, researchers at Johns Hopkins report a complex mathematical method to measure electrical communications within the heart can successfully predict the effectiveness of catheter ablation, the ...

Concerns over side effects of statins stopping stroke survivors taking medication

July 17, 2017
Negative media coverage of the side effects associated with taking statins, and patients' own experiences of taking the drugs, are among the reasons cited by stroke survivors and their carers for stopping taking potentially ...

Study discovers anticoagulant drugs are being prescribed against safety advice

July 17, 2017
A study by researchers at the University of Birmingham has shown that GPs are prescribing anticoagulants to patients with an irregular heartbeat against official safety advice.

Protein may protect against heart attack

July 14, 2017
DDK3 could be used as a new therapy to stop the build-up of fatty material inside the arteries

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.